ERBB2 and endometrial cancer: In the GOG-181B trial, which evaluated trastuzumab as a monotherapy in women with advanced or recurrent endometrial carcinoma, the study failed to meet its target accrual and trastuzumab was considered ineffective for HER2-overexpressing endometrial cancer [114].